Renovia receives 2021 Excellence Award for leva

Global award for Research and Development recognizes Renovia's commitment to generating the highest quality data supporting leva as effective treatment for urinary incontinence   BOSTON, Jan. 6, 2022 /PRNewswire/ -- Renovia Inc. ("Renovia"), a women-led company that...

read more

Renovia's leva® Pelvic Health System is First Femtech Offering Included in Product Library of Digital Therapeutics Alliance Prestigious distinction is further evidence that leva® Pelvic Health System meets rigorous standards for high-quality, evidence-based patient...

read more

Renovia raises $17M in Series C-1 financing

Renovia raises $17M in Series C-1 financing Proceeds to advance U.S. commercial launch of leva® Digital Therapeutic and additional clinical development Renovia Inc. Apr 19, 2021, 09:00 ET BOSTON, April 19, 2021 /PRNewswire/ -- Renovia Inc. ("Renovia"), a women-led...

read more

Renovia presents at Piper Sandler Healthcare Conference

Renovia presents at Piper Sandler Healthcare Conference Medical Technology Disruptors Panel includes Renovia’s leva® Digital Therapeutic, a novel approach for an underreported disorder affecting 20 million women in the U.S. Boston, Mass.—December 1, 2020—Renovia Inc....

read more

Renovia Announces FDA 510(k) Clearance of Next-Generation leva® Pelvic Digital Therapeutic

Boston, MA – November 25, 2019 – Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic device and app technologies for women with pelvic floor disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the next-generation leva® Pelvic Digital Therapeutic for the strengthening of pelvic floor muscles and the treatment of stress, mixed and mild to moderate urgency urinary incontinence (UI) in women.

read more